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Activation peptide of the coagulation 
factor XIII (AP-F13A1) as a new biomarker for the 
screening of colorectal cancer
Julien Peltier1,2,3, Jean‑Pierre Roperch2,4, Stéphane Audebert1, Jean‑Paul Borg1 and Luc Camoin1* 
Abstract 
Background: Colorectal cancer (CRC) remains a major cause of cancer fatalities in developed countries. The risk 
of death is correlated to the stage of CRC during the primary diagnosis. Early diagnosis is closely associated with 
enhanced survival rate. We therefore investigated the AP‑F13A1 as a potential protein marker of CRC.
Methods: The protein expression of FXIII in 40 serum samples was evaluated by enzyme‑linked immunosorbent 
assays. Additionally, targeted proteomic assays (LC‑PRM) were used to evaluate the expression of the activation 
peptide of F13A1 (AP‑F13A1) in a further 113 serum samples. Results were analyzed by the Wilcoxon test and receiver 
operating characteristic curves generated to assess statistical differences and diagnostic factors between CRC patients 
and controls.
Results: AP‑F13A1 was quantified in human serum samples using calibration curves with excellent linearity. AP‑
F13A1 was reduced in CRC patients using PRM assays from two distinct biobanks. The AUC for AP‑F13A1 were 0.95 
and 0.93. Sensitivity/specificity values for the two sets of patients were 75%/95% and 71%/95% respectively.
Conclusion: We have presented the proof of principle that in vivo release of AP‑F13A1 can be measured by PRM‑
based strategies in CRC serum samples. AP‑F13A1 may be an effective serological biomarker as part of a screening 
program of CRC detection.
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Background
Colorectal cancer (CRC) remains a major cause of cancer 
mortality throughout the world with an annual incidence 
of approximately 1 million cases and an annual mortality 
of around 700,000. Western lifestyle and the aging popu-
lation are the major factors accounting for the increased 
incidence of CRC [1]. CRC outcome is highly depend-
ent upon the stage of detection. The 5-year survival rate 
of patients with metastases (stage III + IV) is less than 
30%, while patients with localized adenomatous polyps 
(Stage I + II) have an excellent outcome with a 80% 5-year 
survival rate [2]. Unfortunately, initial clinical symptoms 
often occur at the advanced stage of CRC, when the dis-
ease has already progressed and spread beyond the colon. 
Detecting CRC by iFOBT in average risk individuals, i.e. 
asymptomatic 50–75  years individuals, can impact sur-
vival [3]. The iFOBT which uses specific antibodies for the 
globin portion of human haemoglobin to screen for blood 
in stool samples, has an acceptable  95% specificity but 
poor sensitivity of detection in the asymptomatic popula-
tion (27% sensitivity for adenoma, 65% sensitivity for car-
cinoma) [3]. Presently, there is no noninvasive alternative 
to the recommended screening FOBT test [4]. Discovery 
of new non invasive biomarkers with greater diagnostic 
power are required to develop a more sensitive, reliable 
and non-invasive test for all forms of CRC [5].
A biomarker is defined as a biological indicator of the 
physiology and the pathological condition of patients 
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and can be characterized by analysing blood milieu. We 
assume that comparison of blood samples from patients 
with adenomatous polyps or CRC will contain a molecu-
lar signature resulting from tissue damage or tumor pro-
duction that will be different from the blood of healthy 
patients. In clinical laboratories, ELISA or other immu-
noassays are often the “gold standard” method to detect 
and quantify the protein expression with high through-
put analysis with and an outstanding sensitivity. How-
ever, the limited specificity of many ELISAs and the cost 
for development put limitations on blood biomarkers [6]. 
An alternative approach based on the absolute quantifi-
cation of molecules using mass spectrometry and single 
reaction monitoring (SRM) or parallel reaction monitor-
ing (PRM) has been successfully implemented in clini-
cal assays for monitoring drugs, metabolites and more 
recently proteins and peptides [7–9]. The SRM/PRM 
methods have the advantage of rapid and high specificity 
of detection for monitoring both the intact peptide mass 
and their fragments during LC–MS analysis.
Our group reported recently an iTRAQ-based prot-
eomic strategy in different clinical stages of CRC [10]. 
In that discovery study, we selected a panel of potential 
biomarkers for evaluation on individual patients. One 
particular protein of interest, the coagulation factor 
XIII-A (F13A1) was identified as one of the key down-
regulated proteins. In the present study, we develop and 
describe the outstanding potential of LC–MS/MS and 
PRM assays for quantifying and validating the endog-
enous F13A1 in cohorts of human serum samples at dif-
ferent stage of colorectal cancer. AP-F13A1 was found as 
a molecular biomarker that decreased in the serum of the 
CRC patients indicating that it may help in pre-selecting 
patients for colonoscopy.
Methods
Study subjects and sample collections
Human serum samples were taken from two biobank 
collections CCR1 (collection registered under 004-02 of 
CCP Paris-Est) and Valihybritest (ANR-10-BIOT-0012). 
To be eligible for inclusion, the patients had to have no 
previous history of colon or rectal surgery, of diseases 
such as cancer, inflammatory or infectious disease of the 
intestine, and no previous emergency colonoscopy. In all 
cases, serum samples were collected prior to colonos-
copy. The signature of a consent form, approved by the 
ethical committee of Val de Marne Paris-Est area, author-
ized the recruitment of patients in all associated centers. 
Any special diets and medications during this period 
were recorded. The study continued until colonoscopy 
and pathology data had been checked. The final status 
was assigned as “normal colonoscopy (N)” and “cancer at 
colonoscopy (C)”. Samples used in our study were sum-
marized in Table 1. 
Identification of F13A1 peptides
Solid phase extraction‑purification
200  μL of delipidated serum samples [11] were diluted 
5 times in 0.1% TFA prior to C18 solid phase extrac-
tion (SPE). The SPE cartridges (PID# WAT020515, 
Waters) were washed stepwise in 90% ACN and finally 
equilibrated 3 times in 0.1% TFA before the loading of 
diluted serum. Then, the SPE cartridge was washed three 
times with 0.1% TFA to remove binding of non-specific 
Table 1 Clinico-pathological data
Patients were selected randomly from two collections and included for the validation of FXIII by ELISA and AP-F13A1 by PRM assays. For cancer patients, they were 
classified according to cancer’s stage (I, II, III, IV) and the location of the primary tumor
Biobank 1 Biobank 2
Clinical features Control patients (N) Invasive cancer (C) Control patients (N) Invasive cancer (C)
Gender
 Female 12 (57%) 9 (47%) 24 (52%) 16 (59%)
 Male 9 (43%) 10 (53%) 22 (48%) 11 (41%)
Age (years, Median [range]) 52 [19–64] 69 [51–87] 52 [23–81] 66 [27–90]
Weight (kg, Median [range]) 70 [48–115] 70 [50–100] 71 [42–130] 65 [40–89]
Size (cm, Median [range]) 164 [155–193] 168 [157–182] 168 [145–187] 165 [153–185]
Cancer stage
 I 2 (11%) 4 (15%)
 II 5 (26%) 10 (37%)
 III 5 (26%) 7 (26%)
 IV 7 (37%) 6 (22%)
Tumor location
 Right colon 11 (60%) N/A
 Left colon 8 (40%) N/A
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proteins on the C18 reverse phase and elution carried out 
with 70% ACN, 0.1% TFA.
Identification by mass spectrometry
Identifications were carried out on high resolution mass 
spectrometers from Thermo Scientific. The instrument 
method of the Q-Exactive was set-up as follows: Peptide 
fragments were measured in a survey full scan acquired 
in the Orbitrap in the range of m/z 400–5000 at a FWHM 
resolution of 140,000 at 200 m/z. The 12 abundant pre-
cursor ions were selected and HCD fragmentation was 
performed at 25% collision energy. Fragments were 
ejected from the HCD cell and read out in the Orbitrap 
mass analyser at a FWHM resolution of 17,500. Raw files 
generated from mass spectrometry analysis were pro-
cessed with Proteome Discoverer 1.3 (Thermo Fisher 
Scientific). Proteome discoverer was used to search data 
via Mascot against the Human database subset of the 
Uniprot database (version 2013.06) containing 122 191 
entries. Database searches were done using the following 
settings: no enzyme as cleavage, and acetyl N-terminal 
as variable modification. Mass tolerance of 6  ppm and 
0.1 Da were used respectively for precursor and fragment 
ions during search analysis.
ELISA assays
21 sera from healthy patients (N) and 19 from CRC 
patients (C) were extracted from the sample collection 
(Table  1; Biobank 1) and used for the quantification of 
the F13A1 polypeptide, using two commercially available 
ELISA kits according to the manufacturer’s instructions 
PID #ab108836 (Abcam) and PID #E91094Hu (USCN).
PRM assays
Samples preparation
Serum samples were prepared as mentioned in 2.2.1 
using the SPE purification. Samples were dried down 
under vacuum and digested overnight by adding 10 µg of 
trypsin (Promega). The pH was checked to ensure a com-
plete digestion. A second SPE was performed using the 
process previously described above. Samples were dried 
under vacuum and stored at − 80  °C. The overall work-
flow of the study from biomarker discovery to the valida-
tion by LC-PRM is given in Additional file 1.
Optimisation of AP‑F13A1 targets (tAP‑F13A1)
LC–MS experiments were first performed on a LTQ 
Orbitrap Velos to confirm the detection of AP-F13A1 
variants in SPE simplified serum. These experiments 
were accomplished by the use of an inclusion list in the 
mass spectrometry instrument method. Our inclusion 
list consisted of the precursor mass (m/z), charge (z), and 
collision energy for the tryptic peptides produced from 
the tAP-F13A1 (Additional file  2a). The values included 
in the list were provided by the following rules; (1) the 
peptide is fully tryptic and does not contain missed cleav-
age, (2) the m/z value of the peptide is between 400 and 
1500 at a given charge, (3) no modifications are consid-
ered, except the intentional modifications performed on 
the heavy synthetic peptides. Instrument method was 
set up in data dependant mode to switch consistently 
between MS and MS/MS. No signal threshold for an 
MS/MS event was set. Charge state screening was ena-
bled to exclude precursors with 0 and 1 charge states and 
10  s dynamic exclusion was enabled (exclusion list size 
500). For internal mass calibration the 445.120025 ion 
was used as lock mass. MS spectra were acquired with 
the Orbitrap in the range of m/z 400–1500 at a FWHM 
resolution of 15,000 at 400 m/z. The included m/z values 
were selected and HCD fragmentation was performed at 
40 and 35% collision energies for two-charge and three 
charge states, respectively. The LTQ Orbitrap instru-
ment was connected to an Ultimate 3000 RSLC (Dionex). 
Upon injection, the fraction was loaded onto the enrich-
ment column (C18 PepMap100, 100 µm I.D, 100 Å pore 
size, 5 µm particle size) using 2% ACN, 0.1% FA. Then the 
analytical column (C18 PepMap100, 75  μm I.D, 100  Å 
pore size, 2 μm particle size) was switched in-line using 
a 35  min multi slope gradient as follows: 3.2% ACN at 
4 min post injection, 20% at 8 min, 40% at 26 min and a 
72% plateau before equilibration for 7 min.
Standard concentration curves
Targeted peptides for AP-F13A1 (tAP-F13A1), two 
light synthetic peptides and two heavy synthetic pep-
tides containing L(13C615N), R(13C615N4), were obtained 
from Thermo Fisher Scientific with purity > 99% (Addi-
tional file  2). The two heavy peptides were as fol-
lows: AVPPNNSNAAEDDL*(13C615N)PTVEL*(13C615N)
QGVVPR*(13C615N4) (tAP-F13A1, valine variant) and 
AVPPNNSNAAEDDLPTVEL*(13C615N)QGL*(13C615N)
VPR*(13C615N4) (tAP-F13A1, leucine variant). Light and 
heavy peptides were spiked together to generate standard 
concentration curves keeping the heavy peptide at 52 ng/ml 
and spanning the light peptide from 13 to 208 ng/mL over 
six concentration points (13, 26, 52, 104, 169 and 208 ng/
mL) Three replicates for each concentration points, from 
the lowest to the highest concentration, were acquired for 
both curves in the SPE simplified serum matrix. The matrix 
used for leucine and valine variant peptides were sera from 
homozygous patients V/V or L/L, respectively.
LC‑PRM of tAP‑F13A1 peptides
For LC-PRM assays, the instrument and the chromato-
graphic method were the same as optimized previously 
in 2.4.2 except for some mass spectrometry settings. 
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The LTQ-Velos Orbitrap was set up in data independent 
mode and using the following parameters for the detec-
tion of MS/MS spectra of tAP-F13A1 peptides (the HCD 
collision activation time of 10 ms, the isolation window 
of 3 m/z and a FWHM resolution of 7500 at 400 m/z dur-
ing fragmentation) (Additional file 2a).
Alternatively, the Q-Exactive instrument was set-up 
as “targeted-MS2” method for the detection of tAP-
F13A1 MS/MS spectra. The included m/z values were 
selected by the quadrupole with a maximum injection 
time of 100 ms and a maximum AGC target of 1e6. HCD 
fragmentation was performed at 25 and 29% collision 
energies for two and three charge states, respectively. 
Fragments were ejected from the HCD cell and read out 
in the Orbitrap mass analyzer at a FMWH resolution of 
35,000 (Additional file 2b).
Data analysis
All quantifications of the tAP-F13A1 peptides were 
performed on Skyline (version 1.4) (http://proteome.
gs.washington.edu/software/skyline) [12]. The peptide 
setting was set to trypsin as cleavage specificity, using no 
missed cleavages and 13C(6)15 N(4) C-term Arginine and 
13C(6)15 N(1) Leucine as specific isotope modifications. 
In addition an MS/MS peptide spectra library generated 
from acquisition of tAP-F13A1 peptides on LTQ-Orbit-
rap and identified using Mascot (Matrix sciences) was 
included in the software (Additional file 3). The spectral 
library provides a quick and accurate procedure to match 
experimental MS/MS spectra with the collection available 
in the library yielding a dot product probability (dotp). 
Details on MS/MS spectra library are given in Additional 
file 3. The spectra filter options were set on two and three 
charge states for precursors, and the four most intense 
“y” fragments were selected for the MS/MS (y12, y11, y7 
and y2; Fig. 2a). MS/MS spectra filtering was set up with 
an isolation width of m/z = 3 at a resolving power of 7500 
(at 400  m/z) and Orbitrap as mass analyser. Both valine 
and leucine variants have been provided for review as 
part of user interface (Additional file 4). MS/MS spectra 
peak picking/integration and the identification/quantifi-
cation of the precursors were done by matching with the 
spectral library. In addition, confident peak integration 
corresponding to the extracted ion chromatogram of the 
four most intense fragments of a selected precursor was 
adjusted manually to avoid potential interferences.
Statistical analysis
Data plot columns, Wilcoxon test calculations and 
receiver operating characteristic (ROC) analysis between 
cancer and controls patients were performed using 
GraphPad Prism version 6.00 for Windows (GraphPad 
Software, San Diego, USA, www.graphpad.com).
Results
Peak candidate identification
LTQ Velos Orbitrap and Q-Exactive mass spectrom-
eters were used to identify F13A1 peptides. Interestingly, 
identified peptides were found to represent the region 
of the activation peptide of the coagulation factor XIII 
A chain (F13A1), also known as the transglutaminase A 
chain (Additional file  5). MS/MS fragmentation high-
lighted the N-terminal acetylation (+ 42.011  Da) as the 
natural post-translational modification. It is of interest 
that this activation peptide of 37 amino acids possesses a 
natural Valine substitution by the Leucine (Val34Leu sub-
stitution) (Additional file 5a, b). At least, 8 tryptic-like frag-
ments (proteoforms of the AP-FX13A1) were identified; 
(Acetyl)-SETSRTAFGGRRAVPPNNSNAAEDDLPTVEL 
QGV(L)VPR (MH+
(Valine) = 3907.964  Da, MH
+
(Leucine) = 
3921.980  Da and MH+
(acetyl+Valine) = 3, 949.011 Da , 
MH+
(acetyl+Leucine) = 3, 963.991 Da) TAFGGRRAVPPNN 
SNAAEDDLPTVELQGV(L)VPR (MH+
(Valine) = 3347.710   
Da and MH+(Leucine) = 3361.723  Da), RAVPPNNSNA 
AEDDLPTVELQGV(L)VPR (MH+
(Valine) = 2758.408  Da 
and MH+(Leucine) = 2772.428) and AVPPNNSNAAEDDL 
PTVELQGV(L)VPR (MH+
(Valine) = 2602.314  Da and 
MH
+
(Leucine) = 2616.322) (Additional file 5c–h).
Serum level of FXIII and FXIII‑A by ELISA assays
Serum levels of FXIII protein were estimated by two dif-
ferent ELISA assays in a cohort of 40 patients (see Table 1, 
Biobank 1). The Abcam ELISA assay (PID# ab108836) 
uses a polyclonal antibody for the detection of FXIII. 
The mean concentration detected in controls and CRC 
patients, were 11.98 ± 3.19 and 9.83 ± 4.01 μg/mL respec-
tively, and were not significantly different by the Wilcoxon 
test calculation (P value = 0.06) (Fig.  1a). Only a signifi-
cant regulation of FXIII was observed in serum of CRC 
patients when divided in two groups, according to the 
pStage I-II (P value = 0.46) and III-IV (**P value = 0.004) 
(Fig. 1a). However, the ROC curve area for the FXIII was 
0.65 (95% CI = 0.82–0.48) discriminating patients with a 
low specificity (40%) and low sensitivity (60%) of detection 
at the cut-off value of 10.70 μg/mL (Fig. 1b). In the USCN 
ELISA assay (E91094Hu) another polyclonal antibody 
against the FXIII was used to determine specific serum 
level. The mean concentrations detected in controls and 
CRC patients, were 10.59 ± 5.88 and 9.99 ± 3.83  μg/mL 
respectively, were not significantly different by the Wil-
coxon test calculation (P value = 0.26) (Fig.  1c). In addi-
tion, non-significant regulation of FXIII was observed in 
serum of CRC patients divided according to the pStage 
I-II and III-IV (Fig.  1c). The AUC calculated was 0.548 
(95% CI = 0.73–0.36) by the use of the USCN ELISA assay. 
The calculated sensitivity and the specificity was 40 and 
60% at the cut off value of 7.70 μg/mL (Fig. 1d).
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Quantitative PRM assay of AP‑F13A1
Optimization of peptide detection by LC–MS
This qualitative step aims to optimize parameters for 
facilitating the development of an assay to allow abso-
lute quantification using high-resolution mass spectrom-
etry (LC PRM-Orbitrap). The isolation and enrichment 
of the AP-FX13A1 proteoforms were achieved by a C18 
SPE cartridge. Only fragments and proteins with low 
molecular weights were bound to the hydrophobic phase. 
Trypsin digestion was carried out to combine all detected 
AP-F13A1 fragments identified in one smaller peptide 
facilitating the development of a quantification assay 
(Additional file  5a–h). Using this strategy, and accord-
ing to the polymorphism of the AP-F13A1, only two tar-
geted peptides were finally screened during LC-PRM 
analyses (AVPPNNSNAAEDDLPTVELQGLVPR and 
AVPPNNSNAAEDDLPTVELQGVVPR are tAP-F13A1 
peptides). The chromatographic gradient was reduced 
to save valuable analysis time. The best compromise was 
an analysis cycle of 35  min with a useful gradient using 
a slope of 1.11% ACN/min from 20% ACN to 40% ACN 
in 18  min. Some settings were maximized on the high-
resolution mass spectrometers. For the Q-Exactive, HCD 
fragmentation was used for the AVPPNNSNAAED-
DLPTVELQGVVPR and the AVPPNNSNAAEDDLPT-
VELQGLVPR peptides. We further demonstrated that 
ionized peptides were available in two and three charge 
states. Depending on these observations, the HCD frag-
mentation has been maximized to 29% when the peptide 
counts a two-charge state and 25% for a three charge state. 
The inclusion list for LC-PRM experiments consisted 
of eight masses derived from the two targeted peptides 
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Fig. 1 Serum concentration of FXIII in healthy patients and patients with declared CRC. Two different commercial ELISA were tested to determine 
the serum level of FXIII; a, b the Abcam ELISA assay (#ab108836) and c, d the ELISA from USCN (#E91094Hu). Receiver operating characteristic (ROC) 
curve of FXIII using the Abcam assay (b) and the USCN assay (d)
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1301.6590++ (dotp 0.88, rdotp 1, total ratio 4.94)
    L [y12] - 1307.7682+ (rank 2)[2] (ratio 4.44)
    P [y11] - 1194.6841+ (rank 1)[1] (ratio 5.31)
    L [y7] - 768.4726+ (rank 4)[4] (ratio 4.93)
    P [y2] - 272.1717+ (rank 3)[3] (ratio 5.08)
1313.6803++ (heavy) (dotp 0.87)
    L [y12] - 1331.8108+ (rank 2)[2]
    P [y11] - 1211.7095+ (rank 1)[1]
    L [y7] - 785.4981+ (rank 4)[3]
    P [y2] - 282.1800+ (rank 3)[4]
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ing the four most intense extracted MS/MS fragments for light (1301.6590; 868.1084) and heavy precursors (1313.6803; 868.1084). b Skyline library 
of MS/MS spectra for the targeted peptides highlighting in blue matching fragments for an injected replicate. ★ highlight the four most intense 
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(tAP-F13A1), the light and heavy forms; 868.108, 872.780, 
876.122, 880.794, 1301.65, 1308.666, 1313.680, 1320.688 
(Additional file 2a, b).
Skyline MS/MS filtering method
The graphical interface for inspecting MS/MS filtered data 
using Skyline is shown in Fig. 2 illustrating the result for 
a homozygous patient Valine/Valine (control patient, P10). 
In this example, the dotp is between 0.87 and 1.00 showing 
an excellent matching of the experimental MS/MS request 
versus the MS/MS pattern available in the library (Fig. 2a, 
b and Additional files 3 and 4). tAP-F13A1 elutes around 
21.5  min and the peak widths are less than 30  s, show-
ing a perfect matching in term of retention time (Fig. 2c). 
The sum of the light/heavy ratios of the four “y” fragments 
intensities (y12, y11, y7 and y2), shows a high reproduc-
ibility between the 3 technical replicates (Fig.  2c, d). In 
addition, the coefficient of variation (CV) for the three 
technical acquisitions for the control patient is around 18% 
(accession number P10), suggesting a correct reproducibil-
ity of quantification (Additional file 6, panel C).
Standard concentration curves
To assess the reproducibility and robustness of the PRM 
assays and the bioinformatic Skyline processing, standard 
concentrations curves were generated in three replicates 
(Fig. 3a, b and Additional file 6, panel A). Light and heavy 
labeled tAP-F13A1 peptides were spiked in simplified 
serum to yield seven concentrations points ranging from 
0 to 208 ng/mL. The simplified serum was processed from 
homozygous patients Valine/Valine or Leucine/Leucine to 
mimic the analytical matrix. These standard concentra-
tion curves demonstrate good linear regressions with good 
inter- and intra- analysis reproducibility. For each peptide 
monitored, the weighted regressions ranged from 0.992 
(tAP-F13A1, valine variant) to 0.995 (tAP-F13A1, leucine 
variant). CVs of the light/heavy ratio peptide were under 
10% except at the lowest concentration point (13 ng/mL) 
with CVs of 15 and 32% for the valine and the leucine 
variants, respectively (Additional file 6, Panel A). The geo-
metric mean across all concentration points was 4.38%, 
suggesting an excellent reproducibility of analyses (Fig. 3c). 
For each tAP-F13A1, the lower limit of detection (LLOD) 
and the lower limit of quantification (LLOQ) were deter-
mined by the following statistical approach described by 
Keshishian and co-workers [13]. The LLOD and LLOQ 
values were determined at 6.3–18.9  and 7.4–22.2  ng/
mL for AVPPNNSNNAAEDDlPTVELQGVVPR and 
AVPPNNSNNAAEDDlPTVELQGLVPR, respectively.
Quantification of AP‑FX13A1 peptides by LC‑PRM
To test the ability of the PRM assay to separate CRC 
patients from controls, we determined the concentration 
of AP-F13A1 variants in a first cohort of 40 volunteers 
(19 cancer patients and 21 controls) (Table  1, Biobank 
1). Serum levels of tAP-F13A1 peptides, AVPPNNS-
NAAEDDLPTVELQGVVPR and AVPPNNSNAAE-
DDLPTVELQGLVPR, were determined by absolute 
quantification, using the AQUA approach. Absolute 
quantities were determined via the ratios of the endog-
enous peptides (light) and the heavy peptides provided 
by the Skyline MS/MS filtering processing. The standard 
concentration curve generated in the simplified serum 
was used for the quantification of tAP-F13A1. By consid-
ering the overall AP-F13A1 heterozygous patients (valine/
leucine isoform) and homozygous patients (valine/valine 
or leucine/leucine isoforms), mean of AP-F13A1 were 
determined to be 181.8 ± 71.0 and 59.4 ± 33.3 ng/mL for 
control and CRC patients respectively which was signifi-
cantly different (****P value < 0.0001) (Fig. 3d). Significant 
regulation of tAP-F13A1 was also observed in serum 
of CRC patients divided in two groups according to the 
pStage I-II and III-IV (Fig. 3d). For tAP-F13A1, the test 
showed a 95% specificity and 75% sensitivity when apply-
ing a cut-off of 95.7  ng/mL. Moreover the diagnostic 
accuracy of the test (AUC) for tAP-F13A1 was 0.955, sug-
gesting that AP-FX13A1 peptides can be considered as 
potential biomarkers for the detection of CRC (Fig. 3f ).
To confirm these initial results, we have determined 
the concentration of AP-F13A1 in a new cohort of 73 
volunteers (27 cancer patients and 46 controls, Table  1; 
Biobank 2). Serum levels of AP-F13A1 were deter-
mined as previously described. Mean concentrations 
of AP-F13A1 were 187.2 ± 92.2  ng/mL (controls) and 
70.4 ± 38.4  ng/mL (CRC) again showing significant dif-
ferences between controls and CRC patients respectively 
(****P value ≤ 0.0001) (Fig.  3e). Significant regulation of 
tAP-F13A1 was again observed in serum of CRC patients 
when divided in two groups according to the pStage 
(Fig. 3e). For AP-F13A1, the test showed 95% specificity 
and 71% sensitivity when applying the same threshold as 
previously calculated. Moreover, the diagnostic accuracy 
of the test (AUC) for AP-F13A1 was 0.93 (Fig.  3g). The 
analyses of ROC curve confirm that AP-F13A1 peptides 
show promise as biomarkers for the detection of CRC. 
CVs from individual patients (3 technical injections) 
and overall concentrations calculated for each individual 
patient are available in Additional file 6, Panel B, C and 
Additional file 7.
Discussion
Early screening for adenoma and CRC has decreased the 
incidence and mortality for CRC [14]. However, current 
methods such as iFOBT have poor sensitivity of detec-
tion in the asymptomatic population (27% sensitivity for 
adenoma, 65% sensitivity for carcinoma) [3]. Presently, 
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there is no non-invasive alternative to FOBT testing in 
screening for CRC, and efforts are now directed toward 
the development of a diagnostic test, more sensitive, 
reliable and specific for CRC using blood markers. In 
our previous quantitative-based proteomics strategy, 
we identified a set of potential protein serum mark-
ers related to the progression of colorectal cancer [10]. 
Some of these potential markers (F9, F10, F12, F13A1, 
F13b, FGA, KLKB1, KNG1, PROC, SERPINA1, SER-
PINA5, SERPINC1, VWF) highlighted a de-regulation 
of the coagulation system. Known association between 
coagulation disorders and cancer dates back to 1865 and 
the Trousseau’s Syndrome, showing a number of coagu-
lation abnormalities which increase tendency to both 
thrombosis and/or haemorrhage of patients with cancer 
[15–17]. Some protein markers of the coagulation system 
are often used as diagnostic and prognostic indicators of 
malignancy [18, 19]. Because F13A1 (FXIIIA) is one the 
last factors involved in the coagulation system that cata-
lyse the polymeric Fibrin in cross-linked Fibrin complex 
[20], we needed to evaluate the F13A1 protein to get 
greater insight into coagulation abnormalities in patients 
with colorectal cancer.
First, FXIII was assessed by ELISA assays in the cohort 
of 40 patients (21 healthy patients and 19 patients with 
CRC; Table  1, Biobank 1). In both ELISA tests, the 
reduced expression of the FXIII were not significantly 
confirmed in the patients with CRC (Fig.  1). Then we 
demonstrated that it was possible to identify the acti-
vated peptide of FXIII (AP-F13A1) in SPE-depleted 
serum using high-resolution mass spectrometry and 
data dependent acquisition. At least 8 tryptic-like forms 
were identified from 25 to 37 amino acids (Additional 
file  5). We used these results to set up a targeted prot-
eomic assay to quantify the F13A1 activation peptide 
(AP-F13A1) in the serum of patients. The development of 
a PRM assay of AP-F13A1 was possible by the optimiza-
tion of sample preparation and mass spectrometry set-
tings. The use of a solid phase extraction (SPE) facilitated 
the isolation and the enrichment of several low abun-
dant proteins, such as cytokines/chemokines, peptides 
hormones along with proteolytic fragments of larger 
proteins, including the 8 proteoforms of AP-F13A1. The 
trypsin digestion allowed us to quantify of all these pro-
teoforms by the selection of the smallest tryptic peptides 
AVPPNNSNAAEDDLPTVELQGV(L)VPR. The quanti-
fication settings were validated in several experimental 
processes, including the step of accurate inclusion mass 
screening [21]. Calibration curves were determined using 
synthetic light and heavy peptides, spiked into the simpli-
fied serum matrix and using the Q-Exactive mass spec-
trometer. For the two peptides, the range was obtained 
over 2 orders of magnitude (Q-Exactive linear slope of 
calibration curves equal to 0.991 and 0.995) (Fig. 3a, b). 
The performance of the method was first evaluated in 
the same cohort of 40 volunteers and then confirmed by 
a cohort of 73 patients from a second biobank (Table 1). 
The quantification of the two isoforms of AP-F13A1 
demonstrated significant discrimination between con-
trols and patients with CRC, indicating that AP-F13A1 is 
down-regulated during progression of CRC (Fig. 3).
The present study supports the concept that ELISA can 
be limiting in the validation process of candidate bio-
markers coming from proteomic analysis. ELISAs used 
in our study were designed to target either the tetrameric 
proenzyme FXIII, F13A1 and F13B but not the specific 
AP-F13A1. To date, there are no suitable antibodies avail-
able for specific screening of the released forms of AP-
F13A1 in the serum of patients through ELISA assays. 
In addition, ELISAs require development for each form 
of AP-F13A1 (Leucine or Valine isoforms), which both 
are time consuming and expensive. Other recent stud-
ies have demonstrated the value of targeted proteomics 
in screening for cancer biomarkers during the preclinical 
evaluation and clinical validation [6, 9, 22, 23]. A possible 
important advantage over immunoassays was the ability 
to include and compare the two different AP-F13A1 iso-
forms in a single PRM experiment. Our data have shown 
that PRM-based evaluation of the different forms of AP-
F13A1 from patients with CRC can be used in the clinical 
environment. In addition, further proteotypic peptides 
can be added to the existing PRM assay, in order to grad-
ually assemble a panel of candidate biomarkers that are 
relevant to the clinical question.
The coagulation factor XIII (FXIII) is a tetrameric pro-
enzyme (FXIII-A2B2) retrieved in the blood, and consists 
of two A subunits (F13A1) and two B subunits (F13B) 
with different molecular functions after the release of 
AP-F13A1. The mean concentration of the proenzyme 
was reported to be 14–28 μg/mL [24]. Our ELISA stud-
ies confirmed similar levels of FXIII expression in the 
blood of patients (11.98 ± 3.19 and 10.59 ± 5.88 μg/mL). 
F13A1 also known as transglutaminase chain A, has 
enzymatic activity and belongs to the transglutaminase 
family. According to the Uniprot entry (http://www.uni-
prot.org/uniprot/P00488), F13A1 consists of 731 amino 
acids (83 kDa) which is acetylated (+ 42.010 Da) on the 
N-terminal of the mature molecule. The major source 
of F13A1 comes from bone marrow cells, but it has also 
been detected in other cell types such as megakaryocytes, 
thrombocytes, monocytes, alveolar macrophages and 
tumor-associated macrophages [25]. During activation 
of F13A1, thrombin cleaves the activation peptide from 
the N-terminus by hydrolyzing the Arg37-Gly38 peptide 
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bond. Other proteases such as MASP1, F10, or trypsin 
have been shown to cleave the Arg37-Gly38 peptide bond 
at lower rate [26]. It is interesting to note that ELISA 
assays revealed average concentration of FXIII protein 
around 10  µg/ml three log higher than the AP-F13A1 
concentration revealed by our PRM assays. The decrease 
of serum AP-F13A1 in CRC patients could be explained 
by the inhibition of these proteases that cleave the acti-
vation peptide of the coagulation F13A1 or the result of 
consumption of AP-F13A1 by proteases of the hemosta-
sis process within the bed of the ulcerated cancer. Sup-
porting this hypothesis, we found some tryptic-like forms 
of AP-F13A1 in patients’ serum. Alternatively, some 
matrix effects in our biological groups could explain this 
decrease, for example carrier proteins in serum could 
bind the AP-F13A1 in CRC patients and then be elimi-
nated by our SPE initial steps. However, the use of acid 
condition for the SPE step is more likely to break peptide/
protein interactions.
F13A1 is the key regulator of coagulation machinery, 
strengthens the fibrin clot by cross-linking fibrin chains 
and protecting fibrin chains from the fibrinolysis [20]. In 
addition, F13A1 exerts other physiological effects associ-
ated with wound-healing, tissue remodeling and tissue 
turnover [27]. It has been demonstrated that F13A1 is 
involved in stimulation of endothelial cell proliferation, 
migration, inhibition of apoptosis and exhibits a proan-
giogenic activity associated with the inhibition of THSB1 
[28]. Although such properties may promote tumorigen-
esis, little is presently known about F13A1 and the con-
sequences of AP-F13A1 polymorphism in human cancer. 
It has been reported, in the Caucasian population, ~ 38% 
are heterozygous for the two isoforms, ~ 56% are homozy-
gous for the valine isoform, and ~ 6% are homozygous for 
the leucine isoform [29, 30]. In the 113 patients included 
in our study, a similar distribution was determined: 28% 
are heterozygous for the two forms, 62% are homozygous 
for the valine isoform and 10% are homozygous for the 
leucine isoform. The prevalence of AP-F13A1 polymor-
phism has been investigated and influence the rate of 
the FXIII cleavage showing an impact on fibrin clot [31], 
but was probably not associated with venous thrombosis 
and progression of adenomatous polyps and CRC [32]. 
However, in a large population-based CRC study, Vossen 
et  al. [29] have recently found a 15% risk reduction for 
heterozygous patients of AP-F13A1. We still cannot con-
firm the hypothesis of Vossen et al., because of the small 
number of samples included in our study (113 patients). 
However, the decrease in AP-F13A1 observed between 
controls and patients with CRC in our study would be 
an indicator of the development and progression of CRC 
toward a stage with a less favorable prognosis.
Conclusion
In summary, we have detected and quantified for the first 
time AP-F13A1 in patients with CRC and presented the 
proof of principle that in vivo release of AP-F13A1 can be 
measured by PRM-based assay. While acknowledging the 
limitations of these two small cohorts of patients, we con-
clude that the measurement of serum AP-F13A1 shows 
potential in distinguishing healthy patients from patients 
with CRC. Further studies are required to elucidate the 
underlying molecular mechanisms in coagulation-depend-
ent signalling pathways in colorectal cancer biology.
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